WilmerHale Advises Underwriters in Follow-on Public Offering of Milestone Pharmaceuticals Inc.

WilmerHale Advises Underwriters in Follow-on Public Offering of Milestone Pharmaceuticals Inc.

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

WilmerHale represented the underwriters in the follow-on public offering of 19,666,667 common shares and 3,333,333 pre-funded warrants to purchase common shares of Milestone Pharmaceuticals Inc., a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. The common shares were issued at a public offering price of $1.50 per share and the pre-funded warrants had a public offering price of $1.499 per pre-funded warrant. The gross proceeds to Milestone were $34.5 million, before deducting underwriting discounts, commissions and offering expenses. The offering closed on March 4, 2024.

The WilmerHale team consisted of Lisa Firenze, Ryan Brewer and Molly Nelson, with assistance from Bruce Manheim, Barish Ozdamar and Meghan Walsh.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel